Igenica Lands $14,000,000 Series C Financing Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    863 Mitten Road Burlingame, CA 94010
  • Company Description
    Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    As we strengthen our product focus, these funds will be used to advance IGN523 through early clinical trials aimed at safety and clinical activity assessments in acute myelogeneous leukemia. It also will enable us to continue to discover and develop new therapeutics based on our innovative ADC platform to expand Igenica’s pipeline and to increase strategic flexibility as we execute on our business and clinical development plans.
  • M&A Terms
  • Venture Investor
    The Column Group
  • Venture Investor
    5AM Ventures
  • Venture Investor
    OrbiMed Advisors
  • Venture Investor
    Third Rock Ventures

Trending on Xconomy